Compare Coursera Inc (COUR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Revvity Inc — how do they compare? Coursera Inc trades at $5.72 (market cap $1.64B), while Revvity Inc trades at $110.91 (market cap $12.41B). The key difference: Revvity Inc is far larger — about 7.6× Coursera Inc's market cap, and Revvity Inc pays a 0.25% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| COUR | RVTY | |
|---|---|---|
Market Cap | $1.64B | $12.41B |
Sector | Consumer Staples | Technology |
52-Week High | $12.70 | $117.75 |
52-Week Low | $5.09 | $82.26 |
Enterprise Value | $890.21M | $14.90B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.67, down 0.7% on the day, with technical indicators showing a bearish trend. The company reported Q1 2026 earnings of $0.07 per share, missing estimates of $0.09, but revenue growth remains positive, reaching $757.5 million in 2025. Recent news highlights the completion of the Udemy merger and a $500 million share repurchase program, while analyst sentiment is mixed with a consensus price target of $8.00.
The outlook for COUR is cautiously optimistic, driven by potential synergies from the Udemy merger and steady revenue growth, though profitability challenges and competitive pressures pose risks. With a 52.94% buy rating from analysts and a 38.5% upside to the consensus target, the stock offers growth potential, but investors should monitor execution on cost management and integration success.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
